Search
Ceftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawnThe EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European … Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug [ceftobiprole medocaril].
Categories: Heterocyclic Compounds, 2-RingDasiglucagon
go.drugbank.com/drugs/DB15226ApprovedAlthough it tends to be more common in type 1 diabetes mellitus, occurring in about 22% to 46% of patients annually, about 7% to 25% of patients with type 2 diabetes mellitus treated with insulin experience … [L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.
Corticorelin ovine triflutate
go.drugbank.com/drugs/DB09067ApprovedIt is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion. … If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease.
Synonyms: Sheep corticotropin-releasing factor (1-41)Mipomersen
go.drugbank.com/drugs/DB05528ApprovedMipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. … It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity.
Categories: Compounds used in a research, industrial, or household setting, Apolipoprotein B-100 Synthesis InhibitorCelecoxib metabolism Pathway
smpdb.ca/view/SMP0000096MetabolicThis in turn inhibits the calcium-dependent events, including PLA2 activation, involved in platelet activation and aggregation. … COX-1 activity in platelets is required for thromboxane A2 (TxA2)-mediated platelet aggregation. Platelet activation and coagulation do not normally occur in intact blood vessels.
Enzymes: Prostaglandin E synthaseAmphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalIt was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. … Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs.
Mixtures: Mixed Salts of a Single-Entity Amphetamine Product, Mixed Salts of a Single-Entity Amphetamine ProductCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigational[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and … It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene.
Mixtures: OTEZLA 10 MG. 20 MG Y 30 MG, OTEZLA 10 MG. 20 MG Y 30 MGCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesJPC-3210
go.drugbank.com/drugs/DB15609ExperimentalIt is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria … JPC-3210 is a potent antimalarial agent.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[A261826] Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal … efficacy of a 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingCeftobiprole medocaril
go.drugbank.com/drugs/DB14733ApprovedCeftobiprole medocaril is a prodrug of [ceftobiprole], a fifth-generation semisynthetic cephalosporin antibacterial. … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European
Categories: Heterocyclic Compounds, 2-RingProducts: ZEVTERA® POLVO LIOFILIZADO, Zevtera 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung